Skip to main navigation Skip to search Skip to main content

Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright's hereditary osteodystrophy

Guiomar Pérez De Nanclares, Eduardo Fernández-Rebollo, Izortze Santin, Beatriz García-Cuartero, Sonia Gaztambide, Edelmiro Menéndez, Maria Jose Morales, Manuel Pombo, José Ramón Bilbao, Francisco Barros, Nuria Zazo, Wiebke Ahrens, Harald Jüppner, Olaf Hiort, Luis Castaño*, Murat Bastepe

*Corresponding author for this work

Abstract

Context: Several endocrine disorders that share resistance to PTH are grouped under the term pseudohypoparathyroidism (PHP). PHP type I, associated with blunted PTH-induced nephrogenous cAMP formation and phosphate excretion, is subdivided according to the presence or absence of additional endocrine abnormalities, Albright's hereditary osteodystrophy (AHO), and reduced Gsα activity caused by GNAS mutations. Objective: We sought to identify the molecular defect in four unrelated patients who were thought to have PHP-Ia because of PTH and TSH resistance and mild AHO features. Methods: Gsα activity and mutation analysis, and assessment of GNAS haplotype, methylation, and gene expression were performed for probands and family members. Results: Two patients showed modest decreases in erythrocyte Gsα activity. Instead of Gsα point mutations, however, all four patients showed methylation defects of the GNAS locus, a feature previously described only for PHP-Ib. Furthermore, one patient with an isolated loss of GNAS exon A/B methylation had the 3-kb STX16 deletion frequently identified in PHP-Ib patients. In all but one of the remaining patients, haplotype analysis excluded large deletions or uniparental disomy as the cause of the observed methylation changes. Conclusions: Our investigations indicate that an overlap may exist between molecular and clinical features of PHP-Ia and PHP-Ib. No current mechanisms can explain the AHO-like features of our patients, some of which may not be linked to GNAS. Therefore, patients with hormone resistance and AHO-like features in whom coding Gsα mutations have been excluded should be evaluated for epigenetic alterations within GNAS.

Original languageEnglish
JournalJournal of Clinical Endocrinology and Metabolism
Volume92
Issue number6
Pages (from-to)2370-2373
Number of pages4
ISSN0021-972X
DOIs
Publication statusPublished - 06.2007

Funding

This work was partially supported by Grant RCMN (C03/08) from the Instituto de Salud Carlos III, Madrid, Spain; a grant from Pfizer Laboratories; grants from the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland (RO1 46718-10 to H.J. and KO1 DK-062973 to M.B.); and a grant from the Bundesministerium für Bildung und Forschung (German Ministry for Research and Education; GFGM01141901 to W.A. and O.H.). G.P.d.N. and J.R.B. are FIS Research Scientists supported by the Spanish Ministry of Health (Fellowship 03/0064 and 99/3076, respectively).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 5 - Gender Equality
    SDG 5 Gender Equality
  3. SDG 10 - Reduced Inequalities
    SDG 10 Reduced Inequalities

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Dive into the research topics of 'Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright's hereditary osteodystrophy'. Together they form a unique fingerprint.

Cite this